Dallas TX 淀粉样变性临床试验
9项针对 淀粉样变性的研究正在 Dallas及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
招募中观察性研究
- Research Site, Dallas
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
招募中3 期
- Clinical Trial Site, Dallas
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
招募中3 期
- Clinical Trial Site, Dallas
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
招募中观察性研究
- Clinical Trial Site, Dallas
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
招募中观察性研究
- University of Texas Southwestern Medical Center, Dallas
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
招募中1/2 期
- UT Southwestern Medical Center, Dallas
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
招募中3 期
- University of Texas Southwestern, Dallas
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
招募中3 期
- Baylor Scott & White Research Institute, Dallas
- University of Texas Southwestern Medical Center, Dallas
Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study
招募中观察性研究
- UT Southwestern Medical Center, Dallas
其他城市的 淀粉样变性试验
- Boston, MA11 项研究
- Rochester, MN10 项研究
- New York City, NY10 项研究
- Philadelphia, PA7 项研究
- St. Louis, MO6 项研究
- Houston, TX6 项研究
- Durham, NC6 项研究
- Baltimore, MD6 项研究
- Portland, OR6 项研究
- Washington, DC5 项研究
- San Diego, CA5 项研究
- Chicago, IL5 项研究
Dallas的其他研究
- 乳腺癌54 项研究
- 非小细胞肺癌52 项研究
- 心力衰竭42 项研究
- 转移性癌症42 项研究
- 癌症(所有类型)38 项研究
- 前列腺癌36 项研究
- 结直肠癌33 项研究
- 肥胖症31 项研究
- 卵巢癌28 项研究
- 膀胱癌27 项研究
- 肺癌27 项研究
- 子宫内膜癌25 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月1日。每项研究自行设定入选标准,由研究团队决定谁能参与。